Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial-Reference-Cited by-同舟云学术

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Published:2012-05 Issue:5 Volume:13 Page:466-475
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zhang Li,Ma Shenglin,Song Xiangqun,Han Baohui,Cheng Ying,Huang Cheng,Yang Shujun,Liu Xiaoqing,Liu Yunpeng,Lu Shun,Wang Jie,Zhang Shucai,Zhou Caicun,Zhang Xiangwei,Hayashi Nobuya,Wang Mengzhao

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;D'Addario;Ann Oncol,2010

3. Treatment of advanced non small cell lung cancer;Bareschino;J Thorac Dis,2011

4. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE);Waters;Br J Cancer,2002

5. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial;Brodowicz;Lung Cancer,2006

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

2. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06

3. Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China;Journal of Medical Economics;2023-10-31

4. The Role of Tyrosine Kinase Inhibitors in Reduction of Mortality from Non-small Cell Lung Cancer: A Meta-analysis;Combinatorial Chemistry & High Throughput Screening;2023-04

5. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer;Cancers;2023-03-14